Dies ist eine Übersichtsseite mit Metadaten zu dieser wissenschaftlichen Arbeit. Der vollständige Artikel ist beim Verlag verfügbar.
IOlBD evidence-based consensus on the use of artificial intelligence for assessment of endoscopic and histologic endpoints in clinical trials of inflammatory bowel disease
0
Zitationen
15
Autoren
2026
Jahr
Abstract
This IOIBD consensus supports the integration of AI/ML into central reading for IBD clinical trials to improve objectivity, efficiency, and consistency, while maintaining human oversight. Further research should address validation, regulatory frameworks, and multimodal integration to enable broader adoption in both trials and clinical practice.
Ähnliche Arbeiten
Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies
2017 · 5.753 Zit.
Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease
2001 · 5.567 Zit.
A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease
2001 · 5.003 Zit.
Host–microbe interactions have shaped the genetic architecture of inflammatory bowel disease
2012 · 4.800 Zit.
Increasing Incidence and Prevalence of the Inflammatory Bowel Diseases With Time, Based on Systematic Review
2011 · 4.781 Zit.
Autoren
Institutionen
- Goethe University Frankfurt(DE)
- Agaplesion Markus Hospital(DE)
- Digestive Health Research Institute(FR)
- Hamilton General Hospital(CA)
- Hamilton Health Sciences(CA)
- Vita-Salute San Raffaele University(IT)
- IRCCS Ospedale San Raffaele(IT)
- Tel Aviv University(IL)
- Rabin Medical Center(IL)
- University College Cork(IE)
- APC Microbiome Institute(IE)
- Western University(CA)
- Mayo Clinic(US)
- Mayo Clinic in Arizona(US)
- Universidade do Porto(PT)
- Hellenic Red Cross(GR)
- Université de Lorraine(FR)
- University of Chicago(US)
- Icahn School of Medicine at Mount Sinai(US)
- Shaare Zedek Medical Center(IL)
- Medical University of Vienna(AT)